ABSTRACT
BACKGROUND: This study is to evaluate the efficacy and adverse reaction of a combination therapy of chemotherapy and laser thermal ablation (LTA) on liver metastases from colorectal cancer. METHODS: Eighty-five cases colorectal cancer liver metastases were assigned to the treatment group (43 cases) and to the control group (42 cases). The treatment group patients received LTA combined with FOLFIRI regimen chemotherapy, and the control group patients only received FOLFIRI regimen chemotherapy. The curative effects, the survival rate and adverse reaction of the two groups were observed and evaluated. RESULTS: Response rate was 53.4% in the treatment group and 38.1% in the control group (P>0.05); disease control rate in the treatment group was 79.1%, higher than 64.3% in control group with significant difference (P<0.01); median progression free survival was 11.8 months in treatment group and 6.8 months in control group (P<0.01); The median overall survival time was 19.1 months in treatment group and 14.9 months in control group (P<0.05). Among the 113 lesions receiving LTA, 104 lesions (92%) were completely destroyed. The main complications of LTA were fever and local pain. The adverse effects between both groups showed no difference. CONCLUSIONS: LTA in combination with chemotherapy of colorectal carcinoma liver metastases is effective and well-tolerated.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/therapy , Colorectal Neoplasms/therapy , Laser Therapy , Liver Neoplasms/therapy , Postoperative Care , Adult , Aged , Carcinoma/mortality , Carcinoma/secondary , Case-Control Studies , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Female , Humans , Kaplan-Meier Estimate , Laser Therapy/methods , Liver Neoplasms/mortality , Liver Neoplasms/secondary , Male , Middle Aged , Treatment OutcomeABSTRACT
Objective To investigate the effect of bevacizumab combined with chemotherapy on the expression of EGFR and HER in the patients with metastatic colorectal cancer .Methods Sixty patients with metastatic colorectal cancer treated in this hos-pital from January 2013 to October 2016 were selected and randomly divided into the experiment group (bevacizumab combined with FOLFOX-6 chemotherapy regimen) and control group (FOLFOX-6 chemotherapy regimen) 30 cases in each group .The curative effects were observed in the two groups .The levels of serum HER and EGFR were detected by enzyme-linked immunosorbent assay (ELISA) .Results The total effective rate after treatment in the experiment group was 53 .33% ,which in the control group was 33 .33% ,the difference was statistically significant (P< 0 .05) .After treatment ,the levels of serum HER and EGHR in the two groups were decreased to some extent ,moreover the experiment group had more decrease than the control group ,the difference be-tween the two groups was statistically significant (P<0 .05) .The occurrence rate of adverse reactions had no statistical difference between the two groups (P>0 .05) .Conclusion Bevacizumab combined with chemotherapy has good effect in the patients with metastatic colorectal cancer .
ABSTRACT
Objective To observe the therapeutic effect of hydrogel dressing for alprostadil-induced phlebitis. Methods Forty-three patients with alprostadil-induced phlebitis were randomly divided into two groups:the treatment group (n= 22),in which hydrogel dressing was applied to affected area,and control group(n = 21),in which mucopolysaccharide polysulfate cream was used to coat the surface of the skin. The curative effects were observed and compared between the two groups. Results The therapy effect on day 7 was superior to that on day 3 in both groups.The curative rate was 86.36% in the treatment group and 47.62% in the control group(P<0.05). Conclusion Hydrogel dressing can effectively treat alprostadil-induced by phlebitis.
